Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64.

Abstract:

:Unlike oncoretroviruses, lentiviral vectors can insert large genes and can target both dividing and nondividing cells; thus they hold unique promise as gene transfer agents. To enhance target range, the native lentiviral envelope glycoprotein is replaced (pseudotyped) with vesicular stomatitis virus G (VSVG), and the genes of interest are packaged in nonreplicating vectors by transient transfection with three plasmids. However, because of cytotoxic effects of VSVG expression in producer cells (293T cells) it has been difficult to generate a packaging cell line, required for even modest scale-up of vector production. Here we introduce a pseudotyped lentivirus vector using the baculovirus GP64 envelope glycoprotein. Compared with VSVG, GP64 vectors exhibited a similar broad tropism and similar native titers. GP64-pseudotyped vectors were usually highly concentrated without much loss of titer. Because, unlike VSVG, GP64 expression does not kill cells, we generated 293T-based cell lines constitutively expressing GP64. Our results demonstrate that the baculovirus GP64 protein is an attractive alternative to VSVG for viral vectors used in the large-scale production of high-titer virus required for clinical and commercial applications.

journal_name

Hum Gene Ther

journal_title

Human gene therapy

authors

Kumar M,Bradow BP,Zimmerberg J

doi

10.1089/10430340360464723

keywords:

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

67-77

issue

1

eissn

1043-0342

issn

1557-7422

journal_volume

14

pub_type

杂志文章
  • Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles.

    abstract::Conditionally replicative adenovirus (CRAd) vectors are designed for specific oncolytic replication in tumor tissues with concomitant sparing of normal cells. As such, CRAds offer an unprecedented level of anticancer potential for malignancies that have been refractory to previous cancer gene therapy interventions. CR...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340152710504

    authors: Li H,Haviv YS,Derdeyn CA,Lam J,Coolidge C,Hunter E,Curiel DT,Blackwell JL

    更新日期:2001-12-10 00:00:00

  • Treating Cystic Fibrosis with mRNA and CRISPR.

    abstract::Less than 20% of the protein coding genome is thought to be targetable using small molecules. mRNA therapies are not limited in the same way since in theory, they can silence or edit any gene by encoding CRISPR nucleases, or alternatively, produce any missing protein. Yet not all mRNA therapies are equally likely to s...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2020.137

    authors: Da Silva Sanchez A,Paunovska K,Cristian A,Dahlman JE

    更新日期:2020-09-01 00:00:00

  • Chemical dimerization of fibroblast growth factor receptor-1 induces myoblast proliferation, increases intracardiac graft size, and reduces ventricular dilation in infarcted hearts.

    abstract::The ability to control proliferation of grafted cells in the heart and consequent graft size could dramatically improve the efficacy of cell therapies for cardiac repair. To achieve targeted graft cell proliferation, we created a chimeric receptor (F36Vfgfr-1) composed of a modified FK506-binding protein (F36V) fused ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.161

    authors: Stevens KR,Rolle MW,Minami E,Ueno S,Nourse MB,Virag JI,Reinecke H,Murry CE

    更新日期:2007-05-01 00:00:00

  • Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.

    abstract::Glycogen storage disease type II (GSDII) is a lysosomal storage disease caused by a deficiency in acid alpha-glucosidase (GAA), and leads to cardiorespiratory failure by the age of 2 years. In this study, we investigate the impact of anti-GAA antibody formation on cross-correction of the heart, diaphragm, and hind-lim...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2005.16.68

    authors: Cresawn KO,Fraites TJ,Wasserfall C,Atkinson M,Lewis M,Porvasnik S,Liu C,Mah C,Byrne BJ

    更新日期:2005-01-01 00:00:00

  • Cancer gene therapy by direct tumor injections of a nonviral T7 vector encoding a thymidine kinase gene.

    abstract::Previously, we described a nonviral cytoplasmic gene therapy vector system based on the T7 autogene concept. This system has been shown to achieve rapid and high levels of gene expression in a variety of animal cells and tissues. To test the utility of the system in vivo tumor ablation, a T7 cancer gene therapy plasmi...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.5-729

    authors: Chen X,Li Y,Xiong K,Aizicovici S,Xie Y,Zhu Q,Sturtz F,Shulok J,Snodgrass R,Wagner TE,Platika D

    更新日期:1998-03-20 00:00:00

  • Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.

    abstract::Genetically modified lymphoblastoid cell lines (LCL) have been shown to be an attractive alternative source of antigen-presenting cells for cancer vaccination in vitro. We tested their application in patients with pancreatic cancer in a phase I clinical trial. As a model tumor antigen, we selected the point-mutated (c...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章

    doi:10.1089/hum.2011.153

    authors: Kubuschok B,Pfreundschuh M,Breit R,Hartmann F,Sester M,Gärtner B,König J,Murawski N,Held G,Zwick C,Neumann F

    更新日期:2012-12-01 00:00:00

  • A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma.

    abstract::Esophageal cancer is characterized by rapid clinical progression and poor prognosis, due to early-stage invasion of adjacent tissues and metastasis. Tissue factor pathway inhibitor-2 (TFPI-2) has been implicated as a metastasis-associated gene in many types of tumors. Here we describe the potential involvement of TFPI...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2008.129

    authors: Ran Y,Pan J,Hu H,Zhou Z,Sun L,Peng L,Yu L,Sun L,Liu J,Yang Z

    更新日期:2009-01-01 00:00:00

  • Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.

    abstract::To target expression of toxic genes to Epstein-Barr virus (EBV)-associated tumor cells, we have developed an EBV-driven enzyme prodrug system (EDEPS) that takes advantage of the trans-activating properties of EBNA1, a latent protein expressed in all EBV-containing cells, to direct expression of cytosine deaminase (CD)...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1996.7.5-647

    authors: Judde JG,Spangler G,Magrath I,Bhatia K

    更新日期:1996-03-20 00:00:00

  • Lentiviral small hairpin RNA knockdown of macrophage inflammatory protein-1γ ameliorates experimentally induced osteoarthritis in mice.

    abstract::Immune cells are involved in the pathogenesis of osteoarthritis (OA). CD4(+) T cells were activated during the onset of OA and induced macrophage inflammatory protein (MIP)-1γ expression and subsequent osteoclast formation. We evaluated the effects of local knockdown of MIP-1γ in a mouse OA model induced by anterior c...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2012.189

    authors: Shen PC,Lu CS,Shiau AL,Lee CH,Jou IM,Hsieh JL

    更新日期:2013-10-01 00:00:00

  • Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors.

    abstract::Adenoviruses are attractive vectors for gene transfer into cardiac muscle. However, their promiscuous tissue tropism, which leads to an ectopic expression of the transgene, is a considerable limitation. To restrict expression to cardiomyocytes, we have constructed two recombinant adenoviruses (Ad-MLC2-250betagal and A...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.13-1919

    authors: Griscelli F,Gilardi-Hebenstreit P,Hanania N,Franz WM,Opolon P,Perricaudet M,Ragot T

    更新日期:1998-09-01 00:00:00

  • Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures.

    abstract::The large amounts of recombinant adeno-associated virus (rAAV) vector needed for clinical trials and eventual commercialization require robust, economical, reproducible, and scalable production processes compatible with current good manufacturing practice. rAAV produced using baculovirus and insect cells satisfies the...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2010.250

    authors: Cecchini S,Virag T,Kotin RM

    更新日期:2011-08-01 00:00:00

  • Efficient rescue of gutted adenovirus genomes allows rapid production of concentrated stocks without negative selection.

    abstract::Gutted adenoviral (Ad) vectors have a greater cloning capacity and elicit less immune response than conventional Ad vectors. Unfortunately, clinical use of gutted vectors has been slowed by production difficulties, including low yield and a tendency for recombinant virus to emerge. These two problems are related, beca...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340252809810

    authors: Hartigan-O'Connor D,Barjot C,Crawford R,Chamberlain JS

    更新日期:2002-03-01 00:00:00

  • A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model.

    abstract::Interleukin (IL)-12 has been reported to induce cellular immune responses for protection against tumor formation. Here we investigate the utility of adenoviral delivery of IL-12 as an adjuvant for a human papillomavirus E7 subunit vaccine in a mouse tumor challenge model. Direct intratumoral injection of AdIL-12 resul...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303403769211619

    authors: Ahn WS,Bae SM,Kim TY,Kim TG,Lee JM,Namkoong SE,Kim CK,Sin JI

    更新日期:2003-10-10 00:00:00

  • Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy.

    abstract::Deficiency of glycogen branching enzyme (GBE) causes glycogen storage disease type IV (GSD IV), which is characterized by the accumulation of a less branched, poorly soluble form of glycogen called polyglucosan (PG) in multiple tissues. This study evaluates the efficacy of gene therapy with an adeno-associated viral (...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2016.099

    authors: Yi H,Zhang Q,Brooks ED,Yang C,Thurberg BL,Kishnani PS,Sun B

    更新日期:2017-03-01 00:00:00

  • Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein.

    abstract::Baculovirus vectors recently have been shown to be capable of efficient transduction of human hepatoma cells and primary hepatocytes in culture. This paper describes the generation of a novel recombinant baculovirus (VGZ3) in which the vesicular stomatitis virus glycoprotein G (VSV G) is present in the viral envelope....

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.17-2011

    authors: Barsoum J,Brown R,McKee M,Boyce FM

    更新日期:1997-11-20 00:00:00

  • Delivery of recombinant gene products to the central nervous system with nonautologous cells in alginate microcapsules.

    abstract::Somatic gene therapy using nonautologous recombinant cells immunologically protected with alginate microcapsules has been successfully used to treat rodent genetic diseases. We now report the delivery of recombinant gene products to the brain in rodents by implanting microencapsulated cells for the purpose of eventual...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950019183

    authors: Ross CJ,Ralph M,Chang PL

    更新日期:1999-01-01 00:00:00

  • Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use.

    abstract::Vectors derived from the human parvovirus AAV-2 (adeno-associated virus type 2) are among the most promising gene delivery vehicles currently being developed. These vectors are not only capable of transducing a large variety of human cell types in vitro and in vivo, but in immunocompetent animal models can establish l...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/10430349950016799

    authors: Grimm D,Kleinschmidt JA

    更新日期:1999-10-10 00:00:00

  • Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.

    abstract::MDA-MB-231, an HLA-A2(+), HER2/neu(+) allogeneic breast cancer cell line genetically modified to express the costimulatory molecule CD80 (B7-1), was used to vaccinate 30 women with previously treated stage IV breast cancer. Expression of CD80 conferred the ability to deliver a costimulatory signal and thereby improved...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章

    doi:10.1089/104303403322124828

    authors: Dols A,Smith JW 2nd,Meijer SL,Fox BA,Hu HM,Walker E,Rosenheim S,Moudgil T,Doran T,Wood W,Seligman M,Alvord WG,Schoof D,Urba WJ

    更新日期:2003-07-20 00:00:00

  • Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents.

    abstract::Immunoisolation of allogeneic cells within a membrane-bound device is a unique approach for gene therapy. We employed an immunoisolation device that protects allograft, but not xenograft, cells from destruction, to implant a human fibroblast line (MSU 1.2) in athymic rodents. Cells, transduced with the MFG-human facto...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.6-879

    authors: Brauker J,Frost GH,Dwarki V,Nijjar T,Chin R,Carr-Brendel V,Jasunas C,Hodgett D,Stone W,Cohen LK,Johnson RC

    更新日期:1998-04-10 00:00:00

  • Gene therapy in ophthalmology: validation on cultured retinal cells and explants from postmortem human eyes.

    abstract::Gene therapy studies in primates can provide important information regarding vector tropism, specific cellular expression, biodistribution, and safety prior to clinical trials. In this study, we report the assessment of transduction efficiency of recombinant adeno-associated virus (rAAV) vectors using human postmortem...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2010.157

    authors: Fradot M,Busskamp V,Forster V,Cronin T,Léveillard T,Bennett J,Sahel JA,Roska B,Picaud S

    更新日期:2011-05-01 00:00:00

  • Cationic phosphonolipids as nonviral gene transfer agents in the lungs of mice.

    abstract::With the aim of developing new gene transfer tools for treating CF with gene therapy, we have synthesized a novel family of molecules named cationic phosphonolipids. The most efficient among them were selected by in vitro screening to compare their activities in vivo in mouse lungs. We used a reporter gene whose activ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.16-2309

    authors: Guillaume-Gable C,Floch V,Mercier B,Audrézet MP,Gobin E,Le Bolch G,Yaouanc JJ,Clément JC,des Abbayes H,Leroy JP,Morin V,Férec C

    更新日期:1998-11-01 00:00:00

  • Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice.

    abstract::Urocortin-2 (UCn2) peptide infusion increases cardiac function in patients with heart failure, but chronic peptide infusion is cumbersome, is costly, and provides only short-term benefits. Gene transfer would circumvent these shortcomings. We previously showed that a single intravenous (IV) injection of AAV8.UCn2 incr...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2014.157

    authors: Lai NC,Gao MH,Giamouridis D,Suarez J,Miyanohara A,Parikh J,Hightower S,Guo T,Dillmann W,Kim YC,Diaz-Juarez J,Hammond HK

    更新日期:2015-06-01 00:00:00

  • Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease.

    abstract::The objective of this phase II investigation is to assess the safety and efficacy of a plasmid mediated approach to induce angiogenesis/arteriogenesis with the angiomatrix protein Del-1 (developmentally regulated endothelial locus 1), in subjects with intermittent claudication (IC) secondary to peripheral arterial dis...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1089/104303404323142060

    authors: Rajagopalan S,Olin JW,Young S,Erikson M,Grossman PM,Mendelsohn FO,Regensteiner JG,Hiatt WR,Annex BH

    更新日期:2004-06-01 00:00:00

  • Production of recombinant adeno-associated virus vectors.

    abstract::Recombinant adeno-associated virus (rAAV) is a prototypical gene therapy vector characterized by excellent safety profiles, wide host range, and the ability to transduce differentiated cells. Numerous rAAV-based vectors providing efficient and sustained expression of transgenes in target tissues have been developed fo...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2005.16.551

    authors: Zolotukhin S

    更新日期:2005-05-01 00:00:00

  • Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12.

    abstract::Mice bearing breast tumors were treated with a single dose of an adenovirus expressing interleukin-12 (AdmIL-12.1) injected intratumorally, which produced regressions in greater than 75% of the treated tumors; approximately one-third of the animals remained tumor free. Complete regression was associated with immunity ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1996.7.16-1995

    authors: Bramson JL,Hitt M,Addison CL,Muller WJ,Gauldie J,Graham FL

    更新日期:1996-10-20 00:00:00

  • Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect.

    abstract::Duchenne muscular dystrophy (DMD) typically occurs as a result of truncating mutations in the DMD gene that result in a lack of expression of the dystrophin protein in muscle fibers. Various therapies under development are directed toward restoring dystrophin expression at the subsarcolemmal membrane, including gene t...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2013.092

    authors: Flanigan KM,Campbell K,Viollet L,Wang W,Gomez AM,Walker CM,Mendell JR

    更新日期:2013-09-01 00:00:00

  • A novel imaging approach for single-cell, real-time analysis of oncolytic virus replication and efficacy in cancer cells.

    abstract::Oncolytic viruses (OV) are novel cancer gene therapies that are moving toward the forefront of modern medicines. However, their full therapeutic potential is hindered by the lack of convenient and reliable strategies to visualize and quantify OV growth kinetics and therapeutic efficacy in live cells. Here, we present ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2020.294

    authors: Quillien L,Top S,Kappler S,Redouté A,Dusetti N,Quentin-Froignant C,Lulka H,Camus C,Buscail L,Gallardo F,Bertagnoli S,Cordelier P

    更新日期:2021-01-27 00:00:00

  • Alpha-1-Antitrypsin Promoter Improves the Efficacy of an Adeno-Associated Virus Vector for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy.

    abstract::Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a devastating disease caused by mutations in TYMP, which encodes thymidine phosphorylase (TP). In MNGIE patients, TP dysfunction results in systemic thymidine and deoxyuridine overload, which interferes with mitochondrial DNA replication. Preclinical stu...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2018.217

    authors: Cabrera-Pérez R,Vila-Julià F,Hirano M,Mingozzi F,Torres-Torronteras J,Martí R

    更新日期:2019-08-01 00:00:00

  • Transient transfection methods for clinical adeno-associated viral vector production.

    abstract::Recombinant adeno-associated virus (AAV)-based vectors expressing therapeutic gene products have shown great potential for human gene therapy. One major challenge for translation of promising research to clinical development is the manufacture of sufficient quantities of AAV vectors that meet stringent standards for p...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2009.064

    authors: Wright JF

    更新日期:2009-07-01 00:00:00

  • Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line.

    abstract::Human immunodeficiency virus (HIV) infection represents one of the most challenging systems for gene therapy. Thanks to the extended knowledge of the molecular biology of the HIV life cycle, many different strategies have been developed including transdominant modifications of HIV proteins, RNA decoys, antisense RNA, ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.5-621

    authors: Michienzi A,Conti L,Varano B,Prislei S,Gessani S,Bozzoni I

    更新日期:1998-03-20 00:00:00